Dasatinib in chronic myeloid leukemia: a review

Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for chronic myeloid leukemia (CML), which provides an identifiable target for developing therapeutic agents. Imatinib mesylate, a BCR-ABL TK inhibitor, is the frontline therapy for CML. Despite the stunning efficacy of this ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilera, Dolly G, Tsimberidou, Apostolia M
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697539/
https://www.ncbi.nlm.nih.gov/pubmed/19536317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697539/
https://www.ncbi.nlm.nih.gov/pubmed/19536317

Ejemplares similares